Skip to main content

Table 1 Baseline demographic and disease characteristics among patients with samples available at baseline

From: Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial

Characteristic

CANA (n = 2353)

PBO (n = 1178)

Total (N = 3531)

Age, year

62.9 ± 7.9

62.6 ± 7.8

62.8 ± 7.9

Female sex, n (%)

779 (33.1)

392 (33.3)

1171 (33.2)

Current smoker, n (%)

410 (17.4)

242 (20.5)

652 (18.5)

History of hypertension, n (%)

2067 (87.8)

1041 (88.4)

3108 (88.0)

History of HF, n (%)

296 (12.6)

171 (14.5)

467 (13.2)

Duration of diabetes, year

13.6 ± 7.5

13.3 ± 7.6

13.5 ± 7.5

Prior history of CV disease, n (%)

1410 (59.9)

695 (59.0)

2105 (59.6)

Prior history of HF, n (%)

171 (14.5)

296 (12.6)

467 (13.2)

BMI, kg/m2

32.7 ± 6.1

32.6 ± 6.2

32.7 ± 6.1

Systolic BP, mmHg

136.3 ± 15.9

137.1 ± 15.7

136.6 ± 15.8

Diastolic BP, mmHg

77.4 ± 9.8

78.1 ± 9.8

77.6 ± 9.8

HbA1c, %

8.2 ± 0.9

8.1 ± 0.9

8.2 ± 0.9

HDL, mg/dL (Median [IQR])

44 [38–52]

44 [38–53]

44 [38–52]

LDL, mg/dL (Median [IQR])

88 [63–108]

82 [63–107]

82 [63–108]

AST, U/L

23.4 (9.8)

23.7 (12.2)

23.5 (10.6)

ALT, U/L

27.0 (14.8)

27.3 (13.9)

27.1 (14.5)

NTproBNP, ng/mL (Median [IQR])

90 [42–205]

96 [42–196]

92 [42–204]

eGFR, mL/min/1.73 m2

77.1 ± 18.8

76.7 ± 19.0

77.0 ± 18.8

ACR, mg/g (Median [IQR])

11.6 (6.5–34.4)

11.5 (6.2–36.0)

11.5 (6.4–34.7)

Normal/mildly increased, n/total (%)

1704/2341 (72.8)

844/1173 (72.0)

2548/3514 (72.5)

Moderately increased, n/total (%)

519/2341 (22.2)

252/1173 (21.5)

771/3514 (21.9)

Severely increased, n/total (%)

118/2341 (5.0)

77/1173 (6.6)

195/3514 (5.5)

  1. Data are mean ± SD unless otherwise indicated
  2. SD standard deviation, HF heart failure, CV cardiovascular, BMI body mass index, BP blood pressure, HDL high density lipoprotein, LDL low density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, NTproBNP N-terminal pro-brain natriuretic peptide, eGFR estimated glomerular filtration rate, ACR albumin:creatinine ratio IQR interquartile range